Overview
Chonluten (EDG) is a synthetic short-chain tripeptide bioregulator formulated specifically to target and repair the mucous membranes of the lungs and bronchial tree.
What problem it targets: It targets chronic bronchitis, respiratory fatigue, smoker's cough, environmental toxin exposure, and compromised bronchial barrier defenses.
What It Does
• Restores bronchial epithelial cell health: Enters bronchial mucosal cells to stimulate normal protein synthesis and accelerate the regeneration of the ciliated epithelial lining.
• Normalizes mucus production and airway defense: Clears excessive, thick bronchial secretions and enhances the respiratory tract's innate protective barrier against pathogens and pollutants.
• Enhances respiratory stamina: Improves oxygen exchange and reduces chronic airway inflammation during exercise or high environmental stress.
• Realistic expectations: Administered in short 10- to 20-day courses. It does not act as an immediate rescue inhaler, but systematically strengthens and rejuvenates respiratory tissue over several weeks.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 20 mg (assumed vial strength) | 2 mL bacteriostatic water (requested mixing example) | 10 mg/mL = 10,000 micrograms/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Presentation
20 mg vial used for the mixing example. Other sizes exist. Confirm the actual peptide content and sequence on the batch documentation.
Protocol
Community protocols & cycle timing
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Common community cycle pattern | 10–20 consecutive days; a few courses per year with months between courses | Compound- and formulation-specific; see rows below | A shared cycle duration does not establish one shared dose. Oral labels may specify 30-day initial courses or 10-day maintenance courses. |
Research study amounts
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Human THP-1 cell model | Cell-culture exposures; schedules varied by assay | See original study methods | 2022 inflammatory-signalling experiment. No clinically validated human amount or route was established here. |
About these protocols
The community rows describe reported experience, not a standard or recommended human regimen. Product-label rows apply to the cited formulation; cell and animal rows describe research models. The 20 mg / 2 mL table is a concentration example using the requested assumptions. Solvent compatibility and stability are product-specific.
Handling & Stacking
- Bioregulators are often discussed as short 10–20-day courses, repeated a few times a year with months between courses, rather than continuous daily use.
- This describes a community cycle pattern, not one universal dose.
- Some finished oral products instead specify a 30-day course or 10-day maintenance course.
- Where users report subcutaneous administration, the abdomen or outer thigh are common subcutaneous sites.
- This does not establish an approved administration route for this compound.
- No compound-specific universal storage temperature or post-mixing stability period was verified.
- Use the supplier’s stability data for that formulation.
- Keep identity, lot, preparation date and final concentration traceable; a purity percentage alone does not establish sterility or stability.
- The named preparation is not established here as an approved treatment for its marketed goals.
- Approved alternatives depend on the diagnosed condition and cannot be assigned from an organ label alone.
